Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas by Kim, Hyeyeung et al.
RESEARCH ARTICLE
Comparative proteomic analysis of low stage and
high stage endometrioid ovarian adenocarcinomas
Hyeyeung Kim1, Rong Wu2, Kathleen R. Cho2, 3, Dafydd G. Thomas2,
Gabrielle Gossner4, J. Rebecca Liu4, Thomas J. Giordano2, 3, Kerby A. Shedden5,
David E. Misek3, 6 and David M. Lubman1, 2, 3, 6
1 Department of Chemistry, University of Michigan, Ann Arbor, MI, USA
2 Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI, USA
3 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
4 Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, MI, USA
5 Department of Statistics, University of Michigan, Ann Arbor, MI, USA
6 Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA
Ovarian cancer, the second most common gynecological malignancy, accounts for 3% of all can-
cers among women in the United States, and has a high mortality rate, largely because existing
therapies for widespread disease are rarely curative. Ovarian endometrioid adenocarcinoma
(OEA) accounts for about 20% of the overall incidence of all ovarian cancer. We have used prote-
omics profiling to characterize low stage (FIGO stage 1 or 2) versus high stage (FIGO stage 3 or 4)
human OEAs. In general, the low stage tumors lacked p53 mutations and had frequent
CTNNB1, PTEN, and/or PIK3CA mutations. The high stage tumors had mutant p53, were
usually high grade, and lacked mutations predicted to deregulate Wnt/b-catenin and PI3K/Pten/
Akt signaling. We utilized 2-D liquid-based separation/mass mapping techniques to elucidate
molecular weight and pI measurements of the differentially expressed intact proteins. We gen-
erated 2-D protein mass maps to facilitate the analysis of protein expression between both the
low stage and high stage tumors. These mass maps (over a pI range of 5.6–4.6) revealed that the
low stage OEAs demonstrated protein over-expression at the lower pI ranges (pI 4.8–4.6) in
comparison to the high stage tumors, which demonstrated protein over-expression in the higher
pI ranges (pI 5.4–5.2). These data suggest that both low and high stage OEAs have characteristic
pI signatures of abundant protein expression probably reflecting, at least in part, the different
signaling pathway defects that characterize each group. In this study, the low stage OEAs were
distinguishable from high stage tumors based upon the proteomic profiles. Interestingly, when
only high-grade (grade 2 or 3) OEAs were included in the analysis, the tumors still tended to
cluster according to stage, suggesting that the altered protein expression was not solely depend-
ent upon tumor cell differentiation. Further, these protein profiles clearly distinguish OEA from
other types of ovarian cancer at the protein level.
Received: July 6, 2007
Revised: November 7, 2007
Accepted: December 20, 2007
Keywords:
Endometrioid ovarian cancer / Liquid-based protein separation / Mass mapping
Proteomics Clin. Appl. 2008, 2, 571–584 571
Correspondence: Dr. David M. Lubman, Department of Surgery,
University of Michigan Medical Center, 1150 West Medical Center
Drive, Room A510B MSRB I, Ann Arbor, MI 48109-0656, USA
E-mail: dmlubman@umich.edu
Fax: 11-734-615-2088
Abbreviations: CF, chromatofocusing; EB, elution buffer; HC,
hierarchical clustering; NPS, nonporous silica; OEA, ovarian
endometrioid adenocarcinoma; PPase 2, pyrophosphatase 2;
RUFY1, RUN and FYVE domain containing protein 1; SB, start
buffer
DOI 10.1002/prca.200780004
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
572 H. Kim et al. Proteomics Clin. Appl. 2008, 2, 571–584
1 Introduction
Ovarian cancer, the second most common gynecological
malignancy, accounts for 3% of all cancers among women in
the United States [1]. Five-year survival rates can be as high
as 94% with early detection of the malignancy. However, as
ovarian cancer is insidious in onset, less than 20% of ovarian
tumors present at early stages of tumor development. The 5-
year survival of women with advanced stage ovarian cancer is
approximately 28%, largely because existing therapies for
widespread disease are rarely curative [1].
Approximately 90% of ovarian cancers are thought to
arise from the ovarian surface epithelium or from surface
epithelial inclusion glands and/or cysts. Epithelial ovarian
cancers (carcinomas) occur as several distinct morphological
subtypes, including serous, endometrioid, clear cell, and
mucinous tumors, based on their appearance under the light
microscope. Combined, serous and endometrioid carcino-
mas account for ,75–80% of all ovarian cancer. Substantial
evidence suggests that the different morphological subtypes
of ovarian carcinoma likely represent biologically and
genetically distinct disease entities [2]. For example, about
85% of mucinous ovarian adenocarcinomas harbor K-RAS
gene mutations, while K-RAS mutations are much less fre-
quently observed in clear cell, endometrioid, and typical
(high grade) serous carcinomas [3–5]. Likewise, mutations of
the CTNNB1 gene (encoding b-catenin) are observed in 16–
38% of ovarian endometrioid adenocarcinomas (OEAs), but
are uncommon in the other types of ovarian carcinomas [6–
11]. As in other cancers, the genes mutated in ovarian cancer
typically encode proteins that function in conserved signal-
ing pathways [12].
Recent investigations of ovarian endometrioid cancers
have provided insights into the signaling pathways dysregu-
lated during ovarian cancer pathogenesis. For example, the
canonical Wnt signaling pathway is frequently deregulated
in OEAs, and usually occurs as a consequence of activating
mutations in the gene (CTNNB1) that encodes b-catenin [7,
9, 13–15]. Similarly, mutations predicted to deregulate the
PI3K/Pten/Akt signaling pathway, such as inactivating
mutations of the PTEN or activating mutations of the PI3K
catalytic subunit, PIK3CA, are also frequently observed in
OEAs [16–18]. More recently, Wu et al. [19] have demon-
strated that OEAs with defects in Wnt/b-catenin and/or
PI3K/Pten/Akt signaling are usually low grade, low stage
tumors, whereas high grade, high stage (stages 3/4) OEAs
typically harbor p53 mutations and lack Wnt/b-catenin and
PI3K/Pten/Akt signaling pathway defects.
Though comprehensive studies of tumor RNA and DNA
have provided a number of insights into ovarian cancer
pathogenesis, proteins are the major effector molecules in
tumor cells. Protein levels may be discordant with corre-
sponding transcript levels, and PTMs can have biologically
critical effects on protein function. To date, a number of
proteomics-based studies have been conducted on ovarian
tumors or on sera from patients with ovarian tumors using
several methods, including 2-D PAGE [20, 21], surface
enhanced laser desorption ionization (SELDI) [22], and 2-D
liquid-based separation methodologies [23, 24]. The latter
methodology not only has greater reproducibility, but also
has the ability to identify and quantify proteins, and the cap-
ability to compare results amongst different sets of experi-
ments and samples [25]. Cancer-specific protein expression
patterns in specific histologic subtypes of ovarian carcino-
mas have not been defined.
In this study, we compared protein expression profiles
for the low stage (FIGO stage 1 or 2) and high stage (FIGO
stage 3 or 4) OEAs. In general, the low stage tumors lacked
p53 mutations and had frequent CTNNB1, PTEN, and/or
PIK3CA mutations, while the high stage tumors were high
grade, had mutant p53 and lacked mutations predicted to
deregulate Wnt/b-catenin and PI3K/Pten/Akt signaling. We
employed 2-D liquid-based separation coupled with ESI-TOF
MS to accurately obtain intact protein molecular weights,
and both MALDI-MS and MALDI-QIT MS for protein iden-
tification. Using these methods, protein expression profiles
of both low and high stage OEAs were obtained from con-
secutive pH ranges (pH 5.6–4.6), and were visualized by a
2-D mass map. We have identified proteins distinguishing
low versus high stage OEA by MS. Interestingly, when only
high-grade (grade 2 or 3) OEAs were included in the analysis,
the tumors still tended to cluster according to stage, sug-
gesting that the altered protein expression was not solely de-
pendent upon tumor cell differentiation. Additionally, we
have demonstrated that the proteomic profiles of OEA are
distinguishable from those of other types of ovarian cancer.
2 Materials and methods
2.1 Sample preparation
We have analyzed twelve OEA tumor samples: six were low
stage (stage 1) and six were high stage (stages 3/4). Further,
two tumors were analyzed twice, using independent tumor
lysates. We also analyzed two OEAs whose staging and
mutational status remained hidden to the investigators until
after completion of experiments within this study. The OEA
proteomic data obtained herein were also compared to pro-
teomic data obtained from a previously published analysis of
16 ovarian clear cell carcinomas and eight ovarian serous
carcinomas [26], using principal component analysis (PCA)
to view tumor interrelationships. The University of Michigan
Institutional Review Board (IRB) approved the experimental
protocol. The OEAs were histologically analyzed and staged
by a board-certified pathologist (K. R. C.) prior to utilization
in this study. The tumor tissues were stored at 2807C until
use. The tissue samples were solubilized in lysis buffer using
a minibead beater (Biospec, Bartlesville, OK). The lysis buf-
fer was composed of 7 M urea (Sigma–Aldrich, St. Louis,
MO), 2 M thiourea (Sigma–Aldrich), 100 mM DTT (Sigma–
Aldrich), 0.2% n-octyl-b-D-glucopyranoside (OG; Sigma–
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Aldrich), 0.5% biolyte ampholytes, pH 3–10 (BioRad, Her-
cules, CA), 10% glycerol (Sigma–Aldrich), and 2% v/v of
506diluted protease inhibitor cocktail solution. The ho-
mogenized tissue samples were incubated at room tempera-
ture for 30 min, then centrifuged (35 0006g, 1 h, 47C) to
pellet insoluble material. The lysed samples were exchanged
from the lysis buffer solution to the buffer solution for fur-
ther chromatofocusing (CF) experiments, using a PD–10G
column (Amersham Bioscience, Piscataway, NJ). The Brad-
ford protein assay (BioRad) was used for protein quantita-
tion.
2.2 CF
CF was performed on a Beckman System Gold model 127s
binary HPLC pump with high-pressure mixer (Fullerton,
CA, USA), and an HPCF 1-D column (2.16250 mm2)
(Eprogen, Darien, IL). Two buffer solutions (a start buffer
(SB) and an elution buffer (EB)) were utilized for the gen-
eration of a pH gradient on the CF column. The SB solution
was composed of 6 M urea and 25 mM Bis-Tris (pH 7.4). The
EB solution was composed of 6 M urea and 10% poly-
buffer74 (pH 3.8). Both buffer solutions were brought to pH
by addition of a saturated solution of iminodiacetic acid. The
CF column was preequilibrated with SB, after which the
mobile phase was switched to EB solution for pH gradient
initiation. The pH gradient was monitored on-line with a
postdetector pH flow cell (Lazar Research Laboratories, Los
Angeles, CA). The UV absorbance of the eluent was mon-
itored on-line at 280 nm. The flow rate was 0.2 mL/min, with
fractions collected in 0.2 pH units. Each fraction was stored
at 2807C until use.
2.3 On-line mass mapping by nonporous silica (NPS)
RP-HPLC with LC-ESI-TOF MS
The second dimensional separation and MW determination
of proteins were performed simultaneously using ESI-TOF
MS (LCT System, Waters-Micromass, Manchester, UK) cou-
pled with NPS RP-HPLC. The separation was performed
with an ODS-I column (4.6633 mm2), which is a packed
column with polymeric C18, 1.5 mm silica (Eprogen). The
UV absorbance was monitored on-line at 214 nm on a Beck-
man 166 System Gold HPLC system. A water/ACN gradient,
containing 0.1% TFA, was used, with 0.3% of formic acid v/v
in 50% ACN solution added separately with a postcolumn
splitter before ESI-TOF MS. The gradient was as follows:
from 5 to 10% in 1 min, 10 to 25% in 1 min, 25 to 35% in
3 min, 35 to 45% in 5 min, 45 to 75% in 10 min, 75 to 100%
in 1 min, 100% in 1 min, and 100 to 5% in 1 min. The flow
rate was 0.4 mL/min for the separation. Approximately 30%
of the eluent from HPLC was delivered on-line to the ESI-
TOF MS, with the remainder collected using an automated
fraction collector. The ESI-TOF MS was set as follows: capil-
lary voltage 3000 V, sample cone 37 V, extraction cone 5 V,
desolvation temperature 2007C, source temperature 1107C,
desolvation gas flow 600 L/h, and maximum nebulizer gas
flow. Prior to each experiment, the instrument was externally
calibrated by direct injection of the NaI/CsI solution. Five
picomolar bovine insulin (Sigma–Aldrich) was added to the
sample for internal standard and normalization. The intact
MW value was determined by deconvoluting the combined
ESI spectra of the protein utilizing Protein Trawler™ (Bio-
Analyte, Portland, ME). The Protein Trawler program allows
fast deconvolution processing based on MaxEnt 1 algorithm
in MassLynx V 4.0 program.
2.4 Trypsin digestion
All of the NPS RP-HPLC sample fractions were lyophilized
to 20 mL, with any remaining TFA neutralized by the addi-
tion of 10% v/v NH4HCO3 into samples. After the addition of
10% v/v DTT and 0.25 mg of TPCK-treated trypsin (Promega,
Madison, WI) to each sample, the samples were vortexed,
and then incubated at 377C for 18 h. The tryptic digestion
was terminated by the addition 2.5% v/v TFA.
2.5 MALDI-MS and MALDI-QIT MS analysis
The digested samples were desalted on 2 mm C18 ZipTips
(Millipore) before spotting onto a MALDI-QITplate. MALDI-
QIT targets were prepared by depositing 0.5 mL of the sample
on the plate with 0.5 mL of matrix solution (1:4 dilution of
saturated CHCA (in 50% ACN, 1% TFA)), containing
50 fmol of angiotensin I, adrenocorticotropin (ACTH, amino
acid 1–17), and adrenocorticotropin (ACTH, 18–39) for the
internal calibration. The mixture was dried at ambient con-
ditions. The delayed extraction reflectron mode was utilized
during MALDI-TOF MS analysis. The operation condition
was as follows: operating voltage 20 kV, extraction voltage
19 950 V, focusing voltage 16 kV, reflectron 24.5 kV, and
nitrogen laser operating 337 nm. The pulse voltage was
2300 V, and sensitivity was 100 mV. Peptide mass spectra,
with a mass range of 800–5000 Da, were obtained during
MALDI-TOF MS analysis. The matrix solution for MALDI-
QIT was prepared from DHB (2,5,-dihydroxybenzoic acid) in
50% ACN, 0.1% TFA. Data acquisition and processing dur-
ing MALDI-QIT-TOF analysis were controlled by Kratos
“Launchpad” software, with the standard instrument setting
for optimum transmission at medium mass. The MALDI-
QIT-TOF was externally calibrated using fullerite deposited
directly onto the plate. The data acquired from MALDI-TOF
MS analysis were searched in MS-fit (http://pro-
spector.ucsf.edu/ucsfhtml13.4/msfit.htm) for protein identi-
fication. For the MS-fit, the Swiss-Prot (http://us.expasy.org)
databases were searched using the following parameters: (i)
species: homo sapiens; (ii) maximum number of missed
cleavages: 1; (iii) possible modifications: peptide N-terminal
glutamine to pyroglutamic acid, oxidation of methionine,
protein N-terminus acetylated, and phosphorylation of ser-
ine, threonine, and tyrosine; (iv) peptide mass tolerance:
50 ppm; (v) MW ranged from 1000 to 90 000 Da; (vi) pI range
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of proteins 4–8. The MALDI-QIT-TOF confirmed the identi-
fied proteins by MALDI-MS. The data acquired from
MALDI-QIT-TOF were searched in MASCOT using Swiss-
Prot with the following parameters; (i) species: homo sapiens
(ii) possible modifications: peptide N-terminal glutamine to
pyroglutamic acid, oxidation of methionine, protein N-ter-
minus acetylated, and phosphorylation of serine, threonine,
and tyrosine (iii) peptide tolerance: 1.2 Da (iv) MS/MS toler-
ance: 0.8 Da (v) peptide charge: 11. The following criteria
were used to obtain a confident search result: (i) MOWSE
score was at least 103; (ii) four minimum matched peptides
(iii) two or more consecutive y- or b-series ions for MS/MS;
(iv) total six or more y- or b ions for MS/MS.
2.6 Data analysis
To compare protein expression between low stage (stage 1)
versus high stage (stages 3/4) OEAs, MW and intensity of
proteins obtained by deconvoluting the ESI spectra were
converted to a single text file, and were then transformed by
log10 (max [X 1 100.0] 1 100). Higher abundance proteins
were selected and colored in the mass map if the t-test
p-value of the log-transformed data between the two groups
(low and high stage OEAs) was ,0.05, with 2-fold increase
in the protein expression ratio. Both hierarchical clustering
(HC) and PCA techniques were utilized to view sample rela-
tionships, based upon protein expression similarities. The
HC produced dendrograms in which points are close if they
have greater correlation, found by calculating the Pearson
correlation coefficient. PCA facilitated a 2-D view of protein
expression of different types of ovarian cancer (serous, clear,
endometrioid) at pH 5.4–5.2, thus transforming the dataset
to a new coordinate system such that the greatest variance
from expression dataset turn into the first principal compo-
nent, the second greatest variance becomes the second com-
ponent, and so on. Two components displayed the relation-
ship of the dataset in which similar data are more closely
located. Two sets of protein expression data were compared
by analysis with DeltaVue software (Beckman Coulter), with
each protein map having a different color (red, green) and
differences between the two protein maps shown in a third
map (middle).
2.7 Ovarian tumor tissue microarrays and
immunohistochemistry
Two ovarian tumor tissue microarrays were constructed as
described [27], with the tissues randomly selected from the
University of Michigan Pathology archives. These two tissue
microarrays (combined) contained triplicates of ovarian
tumor samples, including five clear cell carcinomas, 26
ovarian papillary serous carcinomas, six ovarian endome-
trioid carcinomas, 15 metastatic ovarian carcinomas, eight
mixed ovarian serous/endometrioid carcinomas, four ovar-
ian serous/clear cell carcinomas, one papillary serous cysta-
denocarcinoma, and one mixed anaplastic/endometrioid
carcinoma. Immunohistochemistry for Lamin A/C was per-
formed using a mouse mAb (clone JOL2, Chemicon) at 1:50
dilution; immunohistochemistry for S100A9 (Calgranulin B)
was performed using a mouse mAb (Clone 1C10, Novus
Biologicals) at 1:600 dilution. Anti-Lamin A/C and anti-
S100A9 primary antibodies were hybridized to both tissue
microarrays for 30 min at RT using citrate buffer (pH 6.0)
and microwave antigen retrieval (10 min) and the Dako
automated instrument (Dako Cytomation, Carpinteria, CA).
Detection of the primary antibody was performed using the
Dako Envision kit.
3 Results and discussion
In this work, 12 ovarian endometrioid carcinoma tumor sam-
ples (six low stage (stage 1) and six high stage (stages 3/4) were
analyzed in the initial training set by 2-D liquid-based protein
separation methodology. Differentially expressed proteins in
the low stage versus high stage tumors were subsequently
identified using MS. Extracted tumor proteins were resolved
by CF in the first dimensional separation (based on pI), fol-
lowed by NPS RP-HPLC separation in the second dimension
(based on hydrophobicity). Intact protein MW values obtained
by ESI-TOF MS were deconvoluted by Protein Trawler to
generate a list of protein MW and intensities. Proteins were
identified using MALDI-TOF MS, and confirmed by MALDI-
TOF-QIT MS/MS. 2-D mass maps (based upon the intact
protein pI and MW) facilitated comparison of protein expres-
sion between different samples. OEA tumor samples were
categorized as either low stage (stage 1) or high stage (stages
3/4) tumors. Five out of six low stage OEAs had CTNNB1,
PTEN, and/or PIK3CA mutations and lacked p53 mutations.
In contrast, five out of six high stage (stages 3/4) OEAs had
mutant p53 and lacked mutations predicted to deregulate
Wnt/b-catenin and PI3K/Pten/Akt signaling (Table 1).
We used CF to resolve extracted proteins (based upon
protein pI) to compare protein expression profiles associated
with the clinical stage of the tumors. We utilized a pH range
of 5.6–4.6, as the greatest number of the proteins from the
CF column eluted in this range according to the UV absorp-
tion profile. Within the selected pH range, the second
dimensional separation and the ESI-TOF MS were simulta-
neously performed to generate 2-D mass maps displaying
both protein MW and expression level. Moreover, the 2-D
mass maps facilitated comparison of differential protein
expression between the low stage and high stage tumors. A
comparison of the mass maps for low stage and high stage
OEA tumors from pH 5.6 to 4.6, at 0.2 pI intervals, is shown
in Fig. 1. The blue bands represent over-expression of pro-
teins in high stage tumors; the purple bands indicate pro-
teins with over-expression in low stage tumors. Overall, more
proteins were over-expressed in high stage OEAs, than were
over-expressed in low stage OEAs. As shown in Fig. 1, pro-
teins over-expressed in the high stage OEAs were more fre-
quently present in the pI range of 5.4–5.2, whereas proteins
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Table 1. Summary of OEAs utilized in this study









ID Age Stage Grade AA Codon AA Codon (exon) AA Codon (exon) AA Codon (exon) p53
OE-15T 61 1C 3 – – – – – – – – 2
OE-17T 67 1C 2 Ser–Cys 33 – – – – – – 2
OE-20T 69 4 2 – – – – – – – – 1
OE-24T 66 3C 1 – – – – – – Tyr–Asn 236 (Exon 7) 1
OE-25T 58 3 3 – – – – – – Arg–His 273 (Exon 8) 1
OE-28T 73 4 3 – – – – – – – – 1
OE-35T 70 4 3 – – – – – – Stop 196 (Exon 6) 2
OE-37T 40 1A 1 Ser–Cys 37 – – – – – – 2
OE-39T 73 3C 2 – – – – – – Val–Leu 216 (Exon 6) 1
OE-44T 69 1 1 Ser–Cys 33 – – – – – – 2
OE-47T 72 1A 1 Ser–Ala 37 – – – – – – 2
OE-48T 37 1C 1 Gly–Glu 34 Thr–Pro 131 (Exon 5) – – – – 2
OE-71T 49 1C 2 Gly–Val 34 Glu–Lys 542 (Exon 9) – – 2
OE-104T 61 3C 3 – – – – – – Pro–Ser 151 (Exon 5) 1
Figure 1. Comparison of mass maps showing protein expression differences between low stage (stage 1) and high stage (stage 3/4) ovar-
ian endometrioid tumors across several pH ranges. The blue bands represent over-expression of proteins in the high stage tumors. The
purple bands represent over-expression of proteins in the low stage tumors.
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over-expressed in low stage OEAs were more frequently
present in a lower pI range (e.g., pH 4.8–4.6). This subtle pH
change in terms of protein expression based on OEA stages
may indicate post-translational changes in protein expres-
sion during tumor progression.
Differences in protein expression between low stage and
high stage OEAs might be related to the mutational status of
the OEAs. CTNNB1, PTEN, PIK3CA, and/or p53 mutations
may all have profound effects on global protein expression in
the tumor cells. Table 2 indicates the proteins over-expressed
in low stage OEAs. Some of these proteins were previously
identified as candidate markers of ovarian cancer, including
Calgranulin B, and protein phosphatase 2, catalytic subunit,
alpha isoform. Calgranulin B shows the most elevated level
of expression difference between low stage and high stage
OEAs in this study. It is a member of S100 family, and is a
Ca21-binding protein that plays a role in carcinogenesis
through the inhibition of p53, and forms a complex with
calgranulin A to prevent phosphorylation of various mole-
cules necessary for normal transcription and translation [24].
Additionally, calgranulin B serves as a ligand that can bind to
the receptor for advanced glycation end products (RAGE).
This receptor–ligand complex may activate a cellular signal-
ing cascade that influences cell division [28]. Calgranulin B
was previously identified in both cystic ovarian carcinomas
and in the serum of corresponding patients. This protein
may have utility as a diagnostic biomarker to distinguish be-
tween malignant and benign ovarian tumors [29], and may
have utility for the diagnosis of OEA and other forms of
ovarian cancer.
Protein phosphatase 2, catalytic subunit, alpha isoform
(PP2A) has been intensely studied in recent years [30, 31].
We have demonstrated an over-expression of PP2A in the
low stage OEAs. PP2A may regulate the Wnt signaling
pathway at multiple levels [32]. It is plausible that over-
expression of PP2A results as part of futile negative feed-
back in tumors with downstream mutations in the Wnt
signaling pathway. Thus, the over-expression of PP2A pro-
teins in low stage OEAs is not surprising, as five out of six
low stage tumors used in the initial training set have a
mutated CTNNB1 gene encoding b-catenin. Other proteins
of interest in OEA include Ras-related protein Rab1A
(RAB1A), RUN and FYVE domain containing protein 1
(RUFY1), and inorganic pyrophosphatase 2 (PPase 2, PPA2;
Fig. 2). RAB1A is a member of an oncogene family, and
plays a role in the regulation of vesicular transport from the
ER to the Golgi complex [33]. In a study of alternative
mRNA splicing in cancer, the Rab1A transcripts are only
alternatively spliced variants [34], not with the regularly
spliced variants found in normal tissues. The absence of
regularly spliced isoforms may be associated with tumor-
igenesis, although that study did not include analysis of
ovarian cancer. Rab1A protein may be associated with
tumor development. RUFY1 contains C-terminal RUN do-
main and N-terminal FYVE domain with two coiled-coil
domains in between. RUFY1 protein is tyrosine-phospho-
rylated and interacts with Etk (epithelial and endothelial ty-
rosine kinase) through the SH3 and SH2 domains [35]. Al-
though the role of RUFY1 proteins is unclear, interaction
with Etk appears to be involved in the regulation of endo-
cytosis. Inorganic PPase 2 is essential for mitochondrial
function. According to previous studies [36, 37], inorganic
PPase 2 participates in the regulation of cellular pH in the
tumor, and is related to alkaline phosphatase, which reg-
ulates intracellular to extracellular movement of inorganic
pyrophosphate.
Table 3 indicates the over-expressed proteins in the high
stage OEAs, some of which were previously described in
other types of malignancies. For example, ATP synthase D
(Fig. 3) is over-expressed in high stage tumors in the pH 4.8–
4.6 range, and has also been shown to be over-expressed in
lung cancer [38]. It may play an important role in H1 trans-
portation, which is an essential mechanism for tumor adap-
tation in a microenvironment. High-affinity cGMP-specific
30,50-cyclic phosphodiesterase 9A (cIAP1) has been studied
in both lung [39] and cervical cancer [40]. cIAP1 is over-
expressed in lung cancer, and functions as a mediator of
tumor necrosis factor (TNF) receptor signaling. This protein
has antiapoptotic activity [41] and protein expression is
induced by hypoxia [42]. Tumor protein D53 is a member of
Table 2. Over-expressed proteins in low stage (stage 1) ovarian endometrioid tumors










Calgranulin B P06702 13 242/5.7 13 524 5.4–5.2 7.9 1.04E 1 05 54
Ras-related protein Rab-1A
(YPT1-related protein)
P62820-3 13 744/5.4 13 795 5.2–5.0 2 7361 53
E2F transcription factor 7 Q96AV8 14 660/5.1 14 791 5.4–5.2 2.1 5642 36
PP2A, catalytic subunit, alpha isoform P67775 35 571/5.3 35 504 5.6–5.4 2.7 2.11E 1 06 33
Inorganic PPase 2, mitochondrial
precursor (PPase 2)
Q9H2U2 37 963/7.1 38 065 5.4–5.2 2.56 2.29E 1 04 41
Ubiquitin ligase protein RNF8 O76064 55 518/7.1 55 557 5.0–4.8 4.8 8.84E 1 04 41
RUFY1 Q96T51 69 079/5.6 69 153 4.8–4.6 5.5 2.10E 1 06 37
Myotubularin-related protein 6 Q9Y217 71 955/7.6 71 961 5.2–5.0 2 1.28E 1 08 42
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Figure 2. Identification of inor-
ganic pyrophosphatase. QIT-
TOF-MS spectra of the peak for
m/z 1694.8.
Table 3. Over-expressed proteins in high stage (stage 3/4) ovarian endometrioid tumors












ATP synthase D chain, mitochondrial O75947 18 479/5.21 18 594 5.4–5.2 2.39 6689 72
Tumor protein D53 (hD53) (D52-like 1) Q16890 22 449/5.5 22 464 5.4–5.2 2 2.13E 1 05 47
Ras-related protein Rab-14 P61106 23 766/5.8 24 085 5.4–5.2 2.8 1.75E 1 04 44
Potassium channel tetramerization domain
containing protein 4
Q8WVF5 29 996/7.0 29 979 5.4–5.2 2.9 7037 40
Alkaline phosphatase, tissue-nonspecific
isozyme precursor
P05186 57 279/6.2 57 240 5.4–5.2 1.3 6.62E 1 06 33
T-complex protein 1, theta subunit (TCP-1-theta) P50990 59 621/5.4 59 565 5.6–5.4 2 2.90E 1 08 36
Lamin A/C (70 kDa lamin) P02545-2 65 134.8/6.4 65 145 4.8–4.6 1.8 2.93E 1 11 48
High-affinity cGMP-specific 30 ,50-cyclic
phosphodiesterase 9A
O76083 68 493/5.9 68 468 5.4–5.2 7.4 2.58E 1 06 33
Baculoviral IAP repeat-containing protein 2 Q13490 69 899.67/6.27 69 844 5.4–5.2 2.3 2.10E 1 06 37
Vesicle-fusing ATPase P46459 82 655/6.4 82 717 5.2–5.0 2.1 9.86E 1 05 29
Figure 3. Identification of ATP
synthase, synthase D chain,
mitochondrial. QIT-TOF-MS
spectra of peak m/z 1351.6.
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Figure 4. Mass map showing comparison of protein expression between two individual assays from the ovarian endometrioid tumor.
Shown is OE-24T (left) and on the right is a repeat analysis, using a lysate prepared from a different region of the same tumor.
Figure 5. Mass map showing comparison of protein expression between two individual assays from the ovarian endometrioid tumor.
Shown is OE-28T (right) and on the left is a repeat analysis, using a lysate prepared from a different region of the same tumor.
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tumor protein D52 family and its expression is elevated in
breast cancer cells [43]. This protein shows over-expression at
the G2-M transition and is a regulator of cell cycle progres-
sion.
Not all of the proteins identified in our study have
obvious biological relevance in terms of OEA stage. Lamin
A/C is involved in nuclear stability and chromatin structure,
and has been primarily studied in lung cancer [44]. In lung
cancer, the expression of Lamin A/C decreases along with the
expression of other cytoskeletal proteins, including vimen-
tin. However, a previous analysis of ovarian cancer cell lines
demonstrated Lamin A/C over-expression. In the present
study, we have demonstrated a 1.8-fold increase in Lamin
A/C expression in the stage 3/4 tumors that were analyzed.
Interestingly, four out of the eight over-expressed pro-
teins in low stage OEAs are metal binding proteins. In high
stage OEAs, three out of nine over-expressed proteins are
metal binding proteins. Most of the metal binding proteins
are associated with protein structural changes, which may
perturb protein functionality. Further, several ATP and GTP-
binding proteins were over-expressed in the high stage
OEAs. The increased expression of ATP and GTP-binding
proteins in high stage OEAs may be associated with cancer
progression.
In order to confirm the reproducibility of our findings,
we repeated the assays for samples OE-24T and OE-28T.
Thus, tumor OE-24T(R) was actually a second, independent
sample of tumor OE-24T; tumor OE-28T(R) was actually a
Figure 6. Hierarchical clustering dendrogram of the OEAs uti-
lized in this study. Included in the dendrogram are the two repeat
sample analyses (OE-28T(R) and OE-24T(R)), corresponding to
tumors OE-28T and OE-24T, respectively. Also included are the
two tumors (OE-37T and OE-104T) whose stage and mutational
status was not revealed to the investigators until after analysis
was completed. White dot: low stage (stage 1). Black dot: high
stage (stage 3/4).
Figure 7. Mass map comparison of protein expression between OE-47T (right), a stage 1 ovarian endometrioid tumor and OE-37T (left), an
OEA whose stage and mutational status was not revealed to the investigators until after analysis was completed.
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second, independent sample of tumor OE-28T. Both of the
repeated tumor samples were processed in an identical
manner to all the other tumor samples in our study, using
the 2-D liquid-based separation/mass mapping methodol-
ogy. Figure 4 displays the 2-D mass map comparing OE-
24T(R) versus OE-24Tat pH 5.0–4.8. Figure 5 displays the 2-D
mass map comparing OE-28T(R) versus OE-28T at pH 5.4–
5.2. In both cases, the protein bands of the tumor tissue from
the second (independent) analysis matched well with the
protein bands of the tumor tissue from the initial analysis.
As expected, as both of the repeated tumors were high stage
tumors, both tumors partitioned into the high stage tumors
in the dendrogram (Fig. 6).
To determine whether the protein signatures associated
with high stage versus low stage tumors could correctly
classify OEAs of unknown stage, we further analyzed two
OEA (OE-37T and OE-104T) tumors whose staging and
mutational status remained hidden to the investigators until
after completion of experiments contained in this study,
using the 2-D liquid-based separation/mass mapping
methodology. Based upon protein identification and the
mass mapping data described in this study, we have cor-
rectly assigned a clinical stage to both tumor samples. OE-
37T partitioned into the other stage I OEAs in the HC den-
drogram (Fig. 6). At pH 5.4–5.2, the protein bands from OE-
37T matched well with a stage 1 sample, OE-47T (Fig. 7).
OE-37T is a well-differentiated stage 1 OEA with mutant
b-catenin. Figure 7 displays the 2-D mass map comparing
OE-37T versus OE-47T at pH 5.4–5.2. The protein bands
from the OE-37T tissue matched well with the protein
bands in the OE-47T tumor tissue. OE-37T tissue parti-
tioned into the other stage 1 tumors (Fig. 5), as OE-37T has
features similar to those of other stage 1 cancer tissue sam-
ples having mutated CTNNB1 and nuclear b-catenin accu-
mulation, indicating that tumors with similar mutations
may show close relationships in the dendrogram. We also
analyzed a second tumor sample, OE-104T, whose staging
and mutational status remained hidden from the investiga-
tors until after analysis was completed. It clustered into the
high stage OEA group in Fig. 6 and the protein bands at
pH 5.2–5.0 matched well with the bands from OE-39T,
which is a stage 3 OEA (Fig. 8). Indeed, OE-104T is a stage 3
OEA that has a p53 mutation. Figure 8 displays the 2-D
mass map comparing OE-104T versus OE-39T at pH 5.2–5.0.
These results suggest that clustering using proteomic data
alone may help to reveal staging information about the
tumors. Our study shows that it is possible to resolve low
stage OEA from high stage OEA on a proteomic level.
Figure 8. Mass map comparison of protein expression between OE-39T (right), a stage III ovarian endometrioid tumor and OE-104T (left),
an OEA whose stage and mutational status was not revealed to the investigators until after analysis was completed.
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Further, we explored whether we would be able to distin-
guish OEA tumor staging independent of tumor grade
(degree of tumor cell differentiation). To this end, we reana-
lyzed and re-clustered our data, using only the high grade
OEAs (either low or high stage) previously analyzed. We
compared the three (out of six) independent high grade OEAs
that were diagnosed at low stage with the six (out of seven)
independent high grade OEAs that were diagnosed high
stage. Interestingly, although we did not find perfect segrega-
tion of tumor stage in our clustering dendrogram, we did find
that all three low stage OEAs tended to cluster together (Fig. 9).
These results suggest that the altered protein expression was
not solely dependent upon tumor cell differentiation.
The proteomic maps produced in this work may have
utility to classify OEA from other ovarian carcinomas. Gene
expression data suggest that OEA is similar to clear ovarian
cancer in advanced stages and to serous ovarian cancer in the
early stages [45]. We have compared our proteomic data for
endometrioid ovarian carcinomas obtained within to that of
serous and clear cell proteomic data obtained previously [26].
Figure 10 shows the PCA of protein mass map data of three
different subtypes (serous, endometrioid, clear) of ovarian
cancer in the pI range of 5.4–5.2, which is the pI range from
the first dimension separation with the highest abundance of
proteins. It is possible to classify the different subtypes of
ovarian cancer by analysis of proteomic data, thus suggesting
that different subtypes of ovarian cancer may be discernable
at the protein level (Fig. 6).
3.1 Immunohistochemical analysis of Lamin A/C and
S100A9
To further confirm the stage-dependent protein identifica-
tions, Lamin A/C and S100A9 (calgranulin B) expression in
ovarian endometrioid tumors was assessed by immunohis-
tochemistry (Fig. 11), using mouse monoclonal anti-Lamin
Figure 9. Hierarchical clustering dendrogram of only the high
grade (2 and 3) OEAs utilized in this study. Grade 2: 17T, 71T, 20T,
39T; Grade 3: 15T, 25T, 28T, 35T, 104T. White dot: low stage (stage
1). Black dot: high stage (stage 3/4).
A/C and anti-S100A9 antibodies and the ovarian tumor tis-
sue microarrays. Strong nuclear membrane immuno-
reactivity for Lamin A/C was documented (Figs. 11A and B)
in the majority of the ovarian endometrioid tumors. There
were no significant staining differences observed with regard
to tumor stage, in apparent discordance with the findings
from the mass mapping experiments. However, using
immunohistochemistry to discern small differences in pro-
tein expression is difficult. We documented only a 1.8-fold
difference in expression between early and late stage ovarian
endometrioid tumors in the mass mapping experiments.
This fold change in expression levels may not be apparent by
immunohistochemistry. Diffuse and consistent cytosolic
immunoreactivity for S100A9 was documented in early stage
ovarian endometrioid tumors, whereas late stage tumors
exhibited low levels of immunoreactivity (Figs. 11C and D).
These findings were concordant with the findings from the
mass mapping experiments.
Figure 10. PCA analysis of
endometrioid, serous and clear
cell ovarian cancer.
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Figure 11. Immunohistochemical staining of Lamin A/C and S100A9 (calgranulin B). Both early stage (stage 1; A) and advanced stage
(stage 3; B) ovarian endometrioid tumors stained for Lamin A/C immunoreactivity are shown, demonstrating predominantly nuclear
membrane immunoreactivity in the neoplastic cells, with slightly higher immunoreactivity in the advanced stage tumor. Both early stage
(stage 1; C) and advanced stage (stage 3; D) ovarian endometrioid tumors stained for S100A9 immunoreactivity are shown, demonstrating
diffuse and consistent cytosolic immunoreactivity in the neoplastic cells of the early stage tumor (C), with inflammatory cells showing
immunoreactivity in the advanced stage tumor (D).
4 Concluding remarks
Gene expression studies have yielded limited results in dis-
tinguishing endometrioid ovarian cancer from other types
of ovarian cancer. We have demonstrated that the profiling
of proteins in tumor samples, based on pI and molecular
weight using on-line mass mapping, has facilitated the cor-
rect staging of OEA. Protein expression levels for two
tumors whose staging and mutational status were not
revealed to the investigators until after analysis was com-
pleted were predictive of correct tumor stage in mass map-
ping dendrograms. Further, we have demonstrated that
endometrioid ovarian cancer has a unique protein sig-
nature, as compared to other subtypes of ovarian cancer.
Protein profiling can facilitate stage-dependent ovarian
tumor classification.
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National Institutes of Health under grant R01 GM49500
(D.M.L.).
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5 References
[1] Jemal, A., Murray, T., Ward, E., Samuels, A., et al., Cancer
statistics. CA Cancer J. Clin. 2006, 55, 10–30.
[2] Bell, D. A., Origins and molecular pathology of ovarian can-
cer. Mod. Pathol. 2005, 18, S19–S32.
[3] Ichikawa, Y., Nishida, M., Suzuki, H., Yoshida, S. et al., Muta-
tion of K-ras protooncogene is associated with histological
subtypes in human mucinous ovarian tumors. Cancer Res.
1994, 54, 33–35.
[4] Cuatrecasas, M., Villanueva, A., Matias-Guiu, X., Prat, J., K-
ras mutations in mucinous ovarian tumors: A clinico-
pathologic and molecular study of 95 cases. Cancer 1997, 79,
1581–1586.
[5] Enomoto, T., Weghorst, C. M., Inoue, M., Tanizawa, O., Rice, J.
M., K-ras activation occurs frequently in mucinous adeno-
carcinomas and rarely in other common epithelial tumors of
the human ovary. Am. J. Pathol. 1998, 139, 777–785.
[6] Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J. et al.,
Beta-catenin expression pattern in stage I and II ovarian car-
cinomas: Relationship with beta-catenin gene mutations,
clinicopathological features, and clinical outcome. Am. J.
Pathol. 1999, 155, 527–536.
[7] Sagae, S., Kobayashi, K., Nishioka, Y., Sugimura, M. et al.,
Mutational analysis of beta-catenin gene in Japanese ovarian
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
Proteomics Clin. Appl. 2008, 2, 571–584 583
carcinomas: Frequent mutations in endometrioid carcino-
mas. Jpn. J. Cancer Res. 1999, 90, 510–515.
[8] Wright, K., Wilson, P., Morland, S., Campbell, I. et al., Beta-
catenin mutation and expression analysis in ovarian cancer:
Exon 3 mutations and nuclear translocation in 16% of endo-
metrioid tumours. Int. J. Cancer 1999, 82, 625–629.
[9] Wu, R., Zhai, Y., Fearon, E. R., Cho, K. R., Diverse mechan-
isms of beta-catenin deregulation in ovarian endometrioid
adenocarcinomas. Cancer Res. 2001, 61, 8247–8255.
[10] Kildal, W., Risberg, B., Abeler, V. M., Kristensen, G. B. et al.,
Beta-catenin expression, DNA ploidy and clinico-
pathological features in ovarian cancer: A study in 253
patients. Eur. J. Cancer 2005, 41, 1127–1134.
[11] Catasus, L., Bussaglia, E., Rodrguez, I., Gallardo, A. et al.,
Molecular genetic alterations in endometrioid carcinomas
of the ovary: Similar frequency of beta-catenin abnormal-
ities but lower rate of microsatellite instability and PTEN
alterations than in uterine endometrioid carcinomas. Hum.
Pathol. 2004, 35, 1360–1368.
[12] Vogelstein, B., Kinzler, K. W., Cancer genes and the path-
ways they control. Nat. Med. 2004, 10, 789–799.
[13] Palacios, J., Gamallo, C., Mutations in the beta-catenin gene
(CTNNB1) in endometrioid ovarian carcinomas. Cancer Res.
1998, 58, 1344–1347.
[14] Zhai, Y., Wu, R., Schwartz, D. R., Darrah, D. et al., Role of
beta-catenin/T-cell factor-regulated genes in ovarian endo-
metrioid adenocarcinomas. Am. J. Pathol. 2002, 160, 1229–
1238.
[15] Schwartz, D. R., Wu, R., Kardia, S. L., Levin, A. M., Huang, C.
C., Novel candidate targets of beta-catenin/T-cell factor sig-
naling identified by gene expression profiling of ovarian
endometrioid adenocarcinomas. Cancer Res. 2003, 63,
2913–2922.
[16] Tashiro, H., Blaeze, M., Wu, R., Cho, K. R. et al., Mutations in
PTEN are frequent in endometrial carcinoma but rare in
other common gynecological malignancies. Cancer Res.
1997, 57, 3935–3940.
[17] Obata, K., Morland, S. J., Watson, R. H., Hitchcock, A. et al.,
Frequent PTEN/MMAC mutations in endometrioid but not
serous or mucinous epithelial ovarian tumors. Cancer Res.
1998, 58, 2095–2097.
[18] Oda, K., Stokoe, D., Taketani, Y., McCormick, F., High Fre-
quency of coexistent mutations of PIK3CA and PTEN genes
in endometrial carcinoma. Cancer Res. 2005, 65, 10669–
10703.
[19] Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y. et al., Mouse
model of human ovarian endometrioid adenocarcinoma
based on somatic defects in the Wnt/beta-catenin and PI3K/
Pten signaling pathways. Cancer Cell 2007, 11, 321–333.
[20] Ahmed, N., Oliva, K. T., Barker, G., Hoffmann, P. et al., Prote-
omic tracking of serum protein isoforms as screening bio-
markers of ovarian cancer. Proteomics 2005, 5, 4625–4636.
[21] Jones, M. B., Krutzsh, H., Shu, H., Zhao, Y. et al., Proteomic
analysis and identification of new biomarkers and ther-
apeutic targets for invasive ovarian cancer. Proteomics 2002,
2, 76–84.
[22] Petricoin, E. F., III, Ardekani, A. M., Hitt, B. A., Levine, P. J. et
al., Use of proteomic patterns in serum to identify ovarian
cancer. Lancet 1999, 359, 572–577.
[23] Kachman, M. T., Wang, H., Schwartz, D. R., Cho, K. R., Lub-
man, D. M., A 2-D liquid separation/mass mapping method
for interlysate comparision of ovarian carcers. Anal. Chem.
2002, 74, 1779–1791.
[24] Wang, J., Cai, Y., Xu, H., Zhao, J. et al., Expression of MRP14
gene is frequently down-regulated in Chinese human eso-
phageal cancer. Cancer Res. 2004, 14, 46–53.
[25] Hamler, R. L., Zhu, K., Buchannan, N. S., Kreunin, P. et al., A
two-dimensional liquid-phase method coupled with mass
spectrometry for proteomic studies of breast cancer and
biomarker identification. Proteomics 2004, 4, 562–577.
[26] Zhu, Y., Wu, R., Sangha, N., Yoo, C. et al., Classification of
ovarian cancer tissues by proteomic patterns. Proteomics
2006, 6, 5846–5856.
[27] Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M. et
al., Tissue microarrays for high-throughput molecular pro-
filing of tumor specimens. Nat. Med. 1998, 4, 844–847.
[28] Fels, L. M., Buschmann, T., Meuer, J., Reymond, M. A. et al.,
Proteome analysis for the identification of tumor-associated
biomarkers in gastrointestinal cancer. Dig. Dis. 2003, 21,
292–298.
[29] Ott, H. W., Lindner, H., Sarg, B., Mueller-Holzner, E. et al.,
Calgranulins in cystic fluid and serum from patients with
ovarian carcinomas. Cancer Res. 2003, 63, 7507–7514.
[30] Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R.,
Hahn, W. C., Cancer-associated PP2A Aa subunits induce
functional haploinsufficiency and tumorigenicity. Cancer
Res. 2005, 65, 8183–8192.
[31] Polakis, P., Wnt signaling and cancer. Genes Dev. 2000, 14,
1837–1851.
[32] Radcliffe, M. J., Itoh, K., Sokol, S. Y., A positive role for the
PP2A catalytic subunit in Wnt signal transduction. J. Biol.
Chem. 2000, 275, 35680–35683.
[33] Tisdale, E. J., Bourne, J. R., Khosravi-Rar, R., Der, C. J., Balch,
W. E., GTP-binding mutants of rab1 and rab2 are potent in-
hibitors of vesicular transport from the endoplasmic reticu-
lum to the Golgi complex. J. Cell Biol. 1992, 119, 749–761.
[34] Wang, Z., Lo, H. S., Yang, H., Gere, S. et al., Computational
analysis and experimental validation of tumor-associated
alternative RNA splicing in human cancer. Cancer Res. 2003,
63, 655–657.
[35] Yang, J., Kim, O., Wu, J., Qiu, Y., Interaction between tyro-
sine kinase Etk and a RUN domain- and FYVE domain-con-
taining protein RUFY1. A possible role of ETK in regulation
of vesicle trafficking. J. Biol. Chem. 2002, 277, 30219–30226.
[36] Jahde, E., Volk, T., Atema, A., Smets, L. A. et al., pH in human
tumor xenografts and transplanted rat tumors: Effect of
insulin, inorganic phosphate, and m-iodobenzylguanidine.
Cancer Res. 1992, 52, 6209–6215.
[37] Terkeltaub, R. A., Inorganic pyrophosphate generation and
disposition in pathophysiology. Am. J. Physiol. Cell Physiol.
2001, 281, C1–C11.
[38] Chen, G., Gharib, T. G., Huang, C., Thomas, D. G. et al., Pro-
teomic analysis of lung adenocarcinoma: Identification of a
highly expressed set of protein in tumors. Clin. Cancer Res.
2002, 8, 2298–2305.
[39] Dai, Z., Zhu, W. G., Morrison, C. D., Brena, R. M. et al., A
comprehensive search for DNA amplification in lung cancer
identifies inhibitors of apoptosis cIAP1 and cIAP2 as candi-
date oncogenes. Exp. Cell Res. 2004, 298, 535–548.
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
584 H. Kim et al. Proteomics Clin. Appl. 2008, 2, 571–584
[40] Liu, S. S., Tsang, B. K., Cheung, A. N., Xue, W. C. et al., Anti-
apoptotic proteins, apoptotic and proliferative parameters
and their prognostic significance in cervical carcinoma. Eur.
J. Cancer 2001, 37, 1104–1110.
[41] Clem, R. J., Sheu, T. T., Richter, B. W., He, W. W. et al., c-IAP1
is cleaved by caspases to produce a proapoptotic C-terminal
fragment. J. Biol. Chem. 2001, 276, 7602–7608.
[42] Dong, Z., Venkatachalam, M. A., Wang, J., Patel, Y. et al., Up-
regulation of apoptosis inhibitory protein IAP-2 by hypoxia.
Hif-1-independent mechanisms. J. Biol. Chem. 2001, 276,
18702–18709.
[43] Boutrous, R., Bryne, J. A., D53 (TPD 52L1) is a cell cycle
regulated protein maximally expressed at the G-M transition
in the breast cancer cells. Exp. Cell Res. 2005, 310, 152–165.
[44] Waldburg, N., Kahne, T., Reisenauer, A., Rocken, C. et al.,
Clinical proteomics in lung disease. Pathol. Res. Pract. 2004,
200, 147–154.
[45] Schwartz, D. R., Kardia, S. L., Shedden, K. A., Kuick, R. et al.,
Gene expression in ovarian cancer reflects both morphol-
ogy and biological behavior, distinguishing clear cell from
other poor-prognosis ovarian carcinomas. Cancer Res. 2002,
62, 4722–4729.
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
